Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal serous cancer
• •* Stage IIIB, IIIC, or IV
• •* Surgically staged and debulked
• •Complete clinical response after first-line platinum-based chemotherapy (cisplatin or carboplatin) defined by all of the following criteria:
• •* No evidence of cancer by history or physical examination
• •* CA 125 no greater than 35 units/mL
• •* No evidence of residual cancer on CT scan of the abdomen/pelvis and chest x-ray
• •Must have received at least 5 courses of first-line chemotherapy
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •ECOG 0-2
• •Life expectancy
• •Not specified
• •Hematopoietic
• •Granulocyte count at least 1,200/mm\^3
• •Platelet count at least 90,000/mm\^3
• •Hepatic
• •Bilirubin normal
• •ALT and AST less than 1.5 times upper limit of normal (ULN)
• •Alkaline phosphatase less than 1.5 ULN
• •Renal
• •Creatinine clearance at least 60 mL/min
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •No concurrent immunotherapy
• •Chemotherapy
• •See Disease Characteristics
• •At least 3 weeks since prior first-line chemotherapy
• •At least 3 years since other prior chemotherapy (other than first-line chemotherapy for ovarian, fallopian tube, or primary peritoneal cancer)
• •No other concurrent chemotherapy
• •Endocrine therapy
• •No concurrent hormonal therapy
• •Radiotherapy
• •No prior abdominopelvic radiotherapy
• •No concurrent radiotherapy
• •Surgery
• •See Disease Characteristics
• •No concurrent surgery
• •Other
• •No other concurrent antitumor therapy